Stability Testing Course is Taking the Online Training Format by Storm!

LONDON, August 12, 2011 /PRNewswire/ --

5 modules - 2 weeks - all recorded to view anytime!

Pharma IQ is delighted to announce that the Stability Testing Online Training Course is proving to be a key event in the pharma industry agendas.


The secret behind the Stability testing Online Training Course success, apart from the course leader - expert Dr. Manuel Zahn, is its user-friendly format which allows flexible and interactive high standard, global training.

This unique interactive online course will focus on:

  • Understanding the Regulatory Aspects of Stability Testing
  • Temperature Monitoring during Shipment
  • Implementing an Effective Stability by Design Programme,
  • The Evaluation of Stability Data and
  • The Stability Testing for Global Markets.

Set to be the "must attend" pharma online training course, Dr. Manuel Zahn will be leading the following organizations through the challenging world of stability testing:


WuXi AppTec, Inc., Dyax Corp, Pfizer Consumer Healthcare, Procter & Gamble, Bristol-Myers Squibb, Pharmascience Inc., Exova, Novartis Consumer Health SA, Novartis, Novartis Pharma AG, Boehringer Ingelheim Chemicals, Beckman Coulter Inc, C. B. Fleet Company, Inc., Norbrook Laboratories Ltd.


The full Stability Testing Online Training Course delegate profile is available here
http://image.exct.net/lib/ff2912787067/d/1/STABILITY%20DELEGATE%20PROFILE.pdf


With 5 interactive modules, an internet-based official exam for additional accreditation and a A-class leading expert, the Stability Testing Online Training Course will arm you with the necessary skills to develop a robust stability testing programme.

Find the full program, event details and registration information on https://www.stabilitytestingonline.com/index.cfm?utm_campaign=PressRelease(paid)&utm_medium=Online&utm_source=&utm_content=Contentled&utm_term=&sid=%%emailaddr%%&mid=%%memberid%%&MAC=20422.001_PPR

or email [email protected]


A 10% discount will be available when you mention this press release please email Veronica Araujo ([email protected]) to get more information about this offer.


SOURCE Pharma IQ

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.